Effectiveness of redcore lotion in patients with vulvovaginal candidiasis: a systematic review and Meta-analysis.
Meta-analysis
Redcore lotion
candidiasis, vulvovaginal
miconazole
systematic review
Journal
Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
ISSN: 2589-451X
Titre abrégé: J Tradit Chin Med
Pays: China
ID NLM: 8211546
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
22
7
2022
Statut:
ppublish
Résumé
To summarize and evaluate the effectiveness and safety of Redcore lotion on treating vulvovaginal candidiasis (VVC) using a systematic review and Meta-analysis of randomized controlled trials. A systematic literature search was performed in five English and three Chinese electronic databases up to October 2019. Randomized controlled trials in the treatment for VVC were included; only studies which compared the effectiveness and safety of Redcore lotion plus miconazole with miconazole alone were included. Relative risk (RR) and 95% confidence intervals (CI) were used in the Meta-analysis. Seven studies involving 768 patients suffering from VVC were identified; 468 of the patients were pregnant women (60.9%). Combination group (Redcore lotion plus miconazole) was more effective in reduCIng symptomatic episodes of VVC than miconazole alone, with respect to cure rate (RR, 1.31; 95% CI, 1.09-1.57; P = 0.01), fungal culture negative rate (RR, 1.21; 95% CI, 1.04-1.41; P = 0.01), and effective rate (RR, 1.18; 95% CI, 1.05-1.35; P = 0.01). Subgroup analyses for pregnant women also showed that the combination group had superior outcomes with respect to VVC cure rate (RR, 1.48; 95% CI, 1.16-1.88, P < 0.01), fungal culture negative rate (RR, 1.26; 95% CI; 1.09-1.47; P < 0.01), and effective rate (RR, 1.25; 95% CI, 1.10-1.42; P < 0.01). Additionally, the observed risk of adverse events was lower in the combination medication group (RR, 0.30; 95% CI, 0.14-0.65; P < 0.01). Though overall quality of individual studies was low, Redcore lotion plus miconazole can significantly improve clinical effectiveness and safety compared with miconazole alone.
Identifiants
pubmed: 35848964
pii: 1657611056556-111935354
doi: 10.19852/j.cnki.jtcm.2022.04.001
pmc: PMC9924725
doi:
Substances chimiques
Miconazole
7NNO0D7S5M
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
487-492Références
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Cochrane Database Syst Rev. 2001;(4):CD000225
pubmed: 11687074
Obstet Gynecol. 2012 Dec;120(6):1407-14
pubmed: 23168767
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797
Clin Infect Dis. 2015 Dec 15;61 Suppl 8:S759-62
pubmed: 26602614
Molecules. 2019 Nov 27;24(23):
pubmed: 31783502
Lancet Infect Dis. 2018 Nov;18(11):e339-e347
pubmed: 30078662
Infect Drug Resist. 2018 Oct 17;11:1893-1901
pubmed: 30425538
Expert Opin Pharmacother. 2018 Jun;19(9):971-977
pubmed: 29932786
J Obstet Gynaecol Can. 2015 Mar;37(3):266-274
pubmed: 26001874
J Med Microbiol. 2015 Apr;64(Pt 4):390-393
pubmed: 25596116
J Mycol Med. 2020 Sep;30(3):100966
pubmed: 32317216
BMC Womens Health. 2019 Mar 29;19(1):48
pubmed: 30925872
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
J Mycol Med. 2014 Jun;24(2):106-11
pubmed: 24746725
Curr Infect Dis Rep. 2015 Jun;17(6):462
pubmed: 25916994
Stat Med. 1999 Feb 15;18(3):321-59
pubmed: 10070677
Future Microbiol. 2015;10(8):1355-73
pubmed: 26234644